Analysis

    Clinical Trial Markets Are "Ghastly," Critics Say. The Insider Trading Track Record Disagrees.

    NPR called clinical trial prediction markets 'ghastly.' Four confirmed insider trading cases show how platforms already catch and prosecute bad actors.

    By Prediction Markets US Analysis DeskSaturday, August 8, 20268 min read
    Clinical Trial Markets Are "Ghastly," Critics Say. The Insider Trading Track Record Disagrees.

    When Kalshi and Polymarket quietly launched markets allowing traders to bet on the outcomes of clinical trials and FDA drug approvals, the reaction from parts of the research community was swift and visceral.

    "Ghastly," one commentator called it. A Boston University humanities professor whose son is enrolled in a clinical trial told NPR he fears the markets could distort the human experience his son is enduring. A biotech CEO launched a petition calling the practice a threat to "the very foundation of trust and integrity in biotechnology."

    The concern is real and the emotion is understandable. It is also, if the existing enforcement record is any guide, based on a premise about prediction markets that the data has already challenged.

    The Specific Fear

    The critics' argument runs like this: Clinical trial participants — investigators, coordinators, sometimes even patients themselves — have information the broader market does not have. Prediction markets would give those insiders a financial reason to act on that information. A research coordinator who knows a drug is failing could short the approval market. A pharmaceutical employee with early data could front-run the outcome. The financial incentive, critics argue, would subtly corrupt the process of science.

    Nicholas Zaorsky, a professor of radiation oncology at the Mayo Clinic who has helped run clinical trials, articulated the concern precisely to NPR: "Clinical trials are fundamentally different: investigators, coordinators, and sometimes even participants can directly influence aspects of the outcomes being wagered on. That creates financial incentives that risk undermining trial integrity."

    David Tsai, a biotech executive in the San Francisco Bay Area, launched an online petition arguing the markets threaten the integrity of drug development.

    These are serious people raising a serious concern. As a theoretical matter, it is not wrong. But "possible" is doing a lot of work here. The question is whether prediction markets are uniquely incapable of detecting and punishing this kind of conduct — and on that question, the recent record is telling.

    What the Enforcement Record Actually Shows

    Over the past several months, prediction markets have identified and referred to federal authorities four separate insider trading cases across two major platforms. The details of those cases reveal something important about how these markets behave in practice.

    Case 1: The White House Teleprompter Operator. In July 2026, NPR reported that federal regulators were in settlement talks with President Trump's longtime teleprompter operator, who allegedly made nearly $100,000 on Kalshi using advance knowledge of what the president would say at public events. It was the first known instance of officials investigating suspected insider trading on a prediction market from inside the White House. Kalshi's surveillance systems detected the unusual activity and referred the matter to the Commodity Futures Trading Commission.

    Case 2: Former Congressman George Santos. In late July, the CFTC announced that former Representative George Santos had agreed to pay a $35,000 civil penalty and return $17,569 in profits for what the commission called "manipulative activity" on Kalshi. Santos had publicly claimed on social media he would attend President Trump's State of the Union address — driving up the market odds — while simultaneously betting against his own appearance. Kalshi detected the suspicious trades, froze his account, and referred the matter to the DOJ and CFTC within days. Santos is now banned from prediction market trading for three years.

    Case 3: The Special Forces Soldier. In April 2026, federal prosecutors charged a U.S. Army Special Forces soldier with insider trading on Polymarket, alleging he used classified military intelligence about the removal of Venezuelan leader Nicolás Maduro to earn more than $400,000 in trading profits. The soldier pleaded not guilty. The case marked the first criminal insider trading prosecution tied to a prediction market.

    Case 4: The Google Software Engineer. The Department of Justice charged a Google software engineer with using the company's internal data to make more than $1.2 million trading on Polymarket. Prosecutors alleged he had advance access to information about outcomes that had not yet been reflected in public markets.

    Four enforcement actions. Two platforms. Federal criminal charges in two of the four cases. Kalshi CEO Tarek Mansour described his platform's detection process: the Santos trades were flagged "within seconds," and the company received more than a hundred whistleblower complaints in minutes. Kalshi uses AI-powered surveillance tools to identify unusual patterns and employs a dedicated team that refers actionable cases to the CFTC and DOJ.

    The Stock Market Comparison Kalshi Is Making

    Kalshi spokesperson Jack Such put it directly to NPR: "If you want to ban profiting from the failure of clinical trials, you would start with the stock market, where the financial incentive for this type of profit is orders of magnitude larger."

    Short sellers in public equity markets profit from pharmaceutical failures regularly. Biotech stocks routinely move 30 to 50 percent on Phase III clinical trial results, and SEC insider trading enforcement in the pharmaceutical sector runs into dozens of cases a year. The difference Kalshi is highlighting is informational: "The stock market doesn't give any valuable information to researchers," Such told NPR. Prediction markets aggregate dispersed signals from serious analysts — scientists, investors, industry professionals — and produce probability estimates that can inform drug development decisions. The pharmaceutical insider trading risk applies equally, and at far greater financial scale, to equity markets. Critics who are focused on prediction markets appear not to have offered an equivalent petition against short selling in biotech stocks.

    What Kalshi Has Actually Done

    Kalshi has implemented two structural constraints on clinical trial markets that directly address the core concern. The platform says it will offer markets only on late-stage trials — where participants have already been enrolled and their identities are known — which limits the universe of potential insiders to a defined, auditable group. The platform has also announced it will not allow betting on trials where all subjects are minors.

    Neither restriction eliminates the theoretical possibility of insider trading. They do, however, narrow the potential attack surface and create audit trails investigators can follow. The Santos case demonstrated this exactly: Kalshi knew who Santos was, matched his trades to his public statements, and produced documented evidence sufficient to generate a CFTC enforcement order in under six months.

    The Question Critics Are Not Asking

    The critics' framing assumes prediction markets will create insider trading incentives where none previously existed. But clinical trial data is already traded on in equity markets, in options, and in private communications. The question is not whether prediction markets introduce a new risk. The question is whether they introduce a detection mechanism that can identify and deter that risk more effectively than existing alternatives.

    CFTC Chairman Michael Selig has been direct about the agency's stance: "We will aggressively detect, investigate, and, where appropriate, prosecute insider trading in the prediction markets."

    The critics who spoke to NPR are worried about prediction markets. They might also ask why the same level of concern has not historically applied to the equity markets where pharmaceutical insider trading is, by every measure, a larger and better-documented problem.

    What This Means for Anyone Following These Markets

    A few things are verifiable from the existing record:

    • Both Kalshi and Polymarket have demonstrated real insider trading detection capabilities that have produced federal enforcement actions. The Santos case shows a complete pipeline: suspicious trade flagged by AI, account frozen, referral to DOJ and CFTC, enforcement order in under five months.
    • These are not anonymous markets. Kalshi requires identity verification for all users. The same KYC infrastructure that enabled the Santos case applies to every person trading on FDA approval outcomes.
    • Federal regulators are actively watching. The CFTC, which holds exclusive federal jurisdiction over prediction markets, has made insider trading enforcement a stated priority. The agency's chairman has personally committed to aggressive prosecution.

    Clinical trial markets raise genuine ethical questions worth debating. Whether prediction markets are uniquely bad at policing the insider trading concern critics are raising — given four enforcement actions in under a year — is a separate question, and the answer from the data looks different than what NPR's sources assumed.

    Sources & Verification

    Back to Articles